FrançaisParis, France and Camberley, UK – 1 April 2020 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces its monthly update in relation to ordinary shares traded under its ongoing liquidity agreement with Invest Securities SA (the “Liquidity Agreement”). The Liquidity Agreement is governed by French law and is further
Visit PageCategory: Uncategorized
Coronavirus test update, Sales and manufacturing update and COVID-19 test approved in India and Argentina
Paris, France and Camberley, UK – 30 March 2020 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, is pleased to provide an update regarding the novel coronavirus (COVID-19) test developed by Primerdesign, the Company’s molecular diagnostics division based in the UK. http://novacyt.com/wp-content/uploads/2020/03/Novacyt-COVID-19-test-update-ENGLISH-30.03.20.pdf
Visit PageGlobal distribution agreement with Bruker for COVID-19 diagnostic test COVID-19 test receives FDA approval in the Philippines
Paris, France and Camberley, UK – 25 March 2020 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that Primerdesign, its molecular diagnostics division, has signed a global distribution agreement for its COVID-19 test with Bruker-Hain Diagnostics, the molecular diagnostics products business unit of Bruker Corporation (Bruker). http://novacyt.com/wp-content/uploads/2020/03/Novacyt-Covid-19-test-update_Bruker-ENGLISH-25.03.20.pdf
Visit Page